Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months. Why are conventional treatments so limited? Recent scientific advances point to a fundamental cause: therapeutic resistance arises not only from the intrinsic heterogeneity of tumor cells but also from a long-overlooked "tumor microenvironment (TME) ecosystem."

Within this ecosystem, resident microglia and recruited macrophages are not passive bystanders but are actively "educated" by the tumor to become pillars of immunosuppression. They construct a barrier that disables adaptive immunity, creating a paradox of "inflammation without immunity," in which infiltrating lymphocytes are often rendered exhausted and dysfunctional. Beyond immune dysregulation, glioma progression relies on deep interactions with non-immune components of the central nervous system. Groundbreaking studies show that neurons form functional excitatory synapses with glioma cells, driving tumor growth through neurotransmitter release (e.g., glutamate). This activity-dependent growth embeds tumor cells within neural circuits, creating a feed-forward loop. Simultaneously, other brain cells are co-opted: reactive astrocytes enhance invasion via gap junctions and secreted factors while fostering an immunosuppressive niche; Cells of the oligodendrocyte lineage are manipulated to support tumor angiogenesis and immune evasion. Additionally, glioma-induced vascular remodeling results in a leaky and disorganized vascular network that, while fueling tumor metabolism, severely hampers drug delivery.

Thus, the glioma TME acts as both the central conductor of therapeutic failure and an unprecedented source of therapeutic opportunity. The old paradigm of targeting cancer cells alone is shifting toward a more nuanced strategy: disrupting neuron‑tumor communication and reprogramming the immune landscape from suppressive to antitumor states.

This review synthesizes the latest advances in decoding the multilayered glioma TME, with special emphasis on stromal-glioma crosstalk and myeloid cell plasticity, to provide a conceptual framework for next-generation therapies. It marks a fundamental shift in glioma therapeutics: the future battlefield lies in dismantling the entire tumor-supporting ecosystem, not merely eliminating malignant cells-offering new hope in the fight against this devastating disease.